It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
AI Meets Expertise: A hybrid Workflow For Modern Target ID | QIAGEN & Sygnature
In drug discovery, generating targets is no longer the challenge.
The real question is how to identify the few worth investing months of research and significant resources to pursue.
Hear expert perspectives on how AI, pathway analysis and scientific expertise are shaping modern target identification.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Within the Protein Science and Structural Biology department at Sygnature Discovery, we have been utilising the Fida platform (Flow Induced Dispersion Analysis) since its launch in 2024. Within six months, it quickly became an essential tool for our team. Fida has contributed as an analytical tool in a number of our protein projects, as well as enabling stand-alone Fida projects. Here we discuss what Fida is, how Fida has helped us to advance our protein science projects, and how it can benefit our clients. We will also showcase some example data generated at Sygnature to illustrate the potential of Fida.
What is Fida?
Fida is a technique which allows the measurement of a biomolecule’s size (typically proteins for us) in solution. This method uses diffusion under laminar flow to mobilise the sample through a capillary, allowing for the calculation of hydrodynamic radius (Rh) from peak width. At Sygnature, we can follow proteins by intrinsic or labelled fluorescence giving experimental flexibility. Fida is incredibly versatile and can provide a wealth of information on particle size, oligomeric state, buffer effects, protein stability, aggregation, and protein-ligand interaction. It is relatively quick to perform with a standard run taking 6 minutes, and some types of experiment can use just nanolitres of sample.
Fida for QC Analysis
We regularly use Fida for QC analysis on proteins purified at Sygnature where Fida offers a quick homogeneity check (Fig. 1), which is particularly useful for proteins that may be prone to aggregation. We also use Fida to check protein stability over time or a freeze/thaw step, including measuring membrane protein solubility and stability where Fida offers an alternative to techniques such as fluorescent size exclusion chromatography (FSEC; Fig. 2). Fida has been especially useful for large species that are too big for SEC, such as megadalton protein complexes or liposomes, providing a complementary technique to obtain valuable data.
Figure 1. A) SDS-PAGE of 12 subunit protein complex (left) and FIDA analysis (right). B) SEC profile showing 2 populations (top) and FIDA analysis (below). Peak 1 is a soluble oligomer, and Peak 2 is the desired monomeric protein C) Successful labelling of an antibody with Alexafluor 488. Multi-species fit reported two identical sizes (right), indicating a monodisperse sample and no excess free dye.Figure 2. A) Protein instability before (top) and after concentration and dilution (bottom) B) Stability of protein reconstituted into liposomes measured over time.
Measuring Interactions using Fida
Fida is a powerful tool that can be used to measure interactions in solution by monitoring size changes.Kd values can be estimated by measuring the apparent size of the ligand at different analyte concentrations and plotting a binding curve. We have used Fida to measure protein-protein and protein-DNA interactions (Fig. 3).
Figure 3. A) Interaction between Spike-AF488 and ACE2. B) Interaction between protein mutants and FAM labelled DNA.
Fida is an excellent tool for assessing oligomeric state by measuring the absolute size of the analyte and comparing it to expected/predicted sizes. At Sygnature, we have used this to measure protein self-affinity and establish monomeric conditions (Fig. 4) for in-house crystallography projects.
Figure 4. Self association between labelled protein (constant) and titrated unlabelled protein
Where Will Fida Take Us Next
Fida has had a significant impact on most areas of our work. It has been applied to dedicated projects and used as a tool to work smarter, sustaining high interest over multiple projects with several clients. One of the most important features of Fida is its quick time to first result, which allows us to rapidly evaluate protein samples and binding interactions. We can usually determine whether an interaction will be suitable for a Fida study within hours. We have used it to measure protein-protein and protein-ligand interactions, characterise intrinsically disordered proteins, study oligomeric state, and explore PROTACs – and that’s just scratching the surface of Fida’s capabilities, which include applications such measurement of protein aggregation and liquid-liquid phase separation.
Conclusion
Overall, Fida has proven to be an effective, versatile, and valuable platform for the Protein Science and Structural Biology Department at Sygnature Discovery. It has enabled us to advance our protein science projects and offer new capabilities to our clients. We are excited about the future of Fida and the possibilities it holds for our research and our clients.